associate radiation with diseases such as cancer, since the Nuclear Age began in the closing years of the 19th Century we have known that radioisotopes and radiation can be used to image, diagnose, and treat disease. Recently, Kozimor and co-workers have discovered a new way for the large-scale isolation and production of 119 Sb that may enable targeted radiotherapeutic applications (see Figure 1) . 2 This radionuclide shows special promise of potentially delivering lethal doses of radiation to targeted diseased cells, reducing sideeffects by leaving adjacent healthy tissue unharmed.
As early as 1899, X-rays were applied to successfully treat skin cancer. Shortly thereafter, radium from the Curies' laboratory found similar uses in the treatment of Lupus and many forms of cancer.
3 Unfortunately, this was rapidly followed by the misuse of radioactive materials for everything from treating virtually every ailment to making glowing clocks, wristwatch faces, and children's nightlights, and even to intentionally mutating flowering plants to create exotic flowers. 4 Radium became snake oil, and this calamity climaxed with the deaths of the so-called "Radium Girls," who perished from ingesting large amounts of radium while painting watches. 5 Following these events, nuclear medicine continued under many guises for decades thereafter so as not to be lumped in with mistakes of the past, and many books have been written to describe these events both for technical and general audiences. Notably, in the last 20 years, nuclear medicine has become more societally accepted. This shift in perception is perhaps because enough of general public has come to understand that it can be safely applied to ease, and even cure, what ails us. In particular, alpha radiotherapy has emerged over the past decade as one of the best methods for treating disease and, in cases when it cannot be cured, to improve quality of life by easing chronic pain. 6 The most significant advantage of alpha therapy is that this radioactive decay mode delivers all of its energy (typically in the MeV range) to only a few layers of cells. Thus, the damage can be localized to the area where it is needed, such as the destruction of a tumor with minimal damage to the surrounding tissue. Perhaps the bestknown recent victory in this area is the medication Xofigo, whose production was recently acquired by Bayer because of its broad success. 7 Xofigo relies on obtaining 223 Ra from the α-emitter Sb for external use. One particularly creative aspect of this research campaign is that Kozimor and co-workers adopted an unconventional approach for their radiochemical separation method. They made use of X-ray absorption spectroscopy (XAS) at the Stanford Synchrotron Lightsource (SSRL) to guide efforts to remove Te from Sb. This is apparently the first-time synchrotron spectroscopy has been applied to this area of research. The spectroscopic results were valuable and informed researchers on differences between Te and Sb in aqueous solutions and on solid-state chromatographic supports. The information was used to developed a Te/Sb separation procedure that (1) was compatible with large nat Sb (25 g) targets, (2) accounted for safety concerns associated with generating large quantities of 119m Te/ 119 Sb, and (3) could be rapidly (∼36 h separation) carried out using remote handling techniques within hot cells. One of the most interesting discoveries made using this technique is that the Te(IV) was reduced to Te (0) 
